Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER).

Toshikazu MoriwakiYoshinori SakaiHiroyasu IshidaYoshiyuki YamamotoShinji EndoHideaki KuramochiMikio SatoYukimasa HatachiYoshiaki BandoTakashi MaebaKazuto IkezawaMitsuo ShimadaKenji AmagaiMasamitsu MorimotoKazuma KobayashiAkihito TsujiTomohiro NishinaIchinosuke Hyodo

Published in: International journal of clinical oncology (2019)

S-1 on alternate days combined with bevacizumab showed better tolerability and comparable survival compared with the results of similar studies.

Keyphrases

metastatic colorectal cancer
phase ii study
end stage renal disease
open label
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
locally advanced
squamous cell carcinoma
randomized controlled trial
free survival
patient reported
study protocol